Provided by Tiger Trade Technology Pte. Ltd.

Vaxcyte, Inc.

59.28
+0.37500.64%
Volume:1.11M
Turnover:64.82M
Market Cap:8.82B
PE:-7.75
High:60.20
Open:59.47
Low:58.22
Close:58.90
52wk High:65.00
52wk Low:30.81
Shares:148.81M
Float Shares:136.00M
Volume Ratio:1.46
T/O Rate:0.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.6496
EPS(LYR):-5.6333
ROE:-36.51%
ROA:-22.61%
PB:3.20
PE(LYR):-10.52

Loading ...

Should Early VAX-A1 Trial Progress Require Action From Vaxcyte (PCVX) Investors?

Simply Wall St.
·
Jul 07

Vaxcyte COO Jim Wassil Sells 2,250 Common Shares for $127,708.38

Reuters
·
Jul 07

Vaxcyte CEO Grant Pickering Disposes of USD 1.3 Million in Common Shares

Reuters
·
Jun 27

Analysts Offer Insights on Healthcare Companies: Moderna (MRNA) and Vaxcyte (PCVX)

TIPRANKS
·
Jun 26

Vaxcyte Announces Board Transition and New Director Appointment

TIPRANKS
·
Jun 24

Vaxcyte files initial beneficial ownership statement for director Moncef Slaoui

Reuters
·
Jun 24

Vaxcyte names Moncef Slaoui to board after Jacks Lee retirement

Reuters
·
Jun 24

Mizuho Securities Sticks to Its Buy Rating for Vaxcyte (PCVX)

TIPRANKS
·
Jun 21

Vaxcyte (PCVX) Is Up 8.4% After Starting First-in-Human Trial Of Its Strep A Vaccine

Simply Wall St.
·
Jun 19

Vaxcyte President, CFO Andrew Guggenhime sells 10,000 shares for $530,000

Reuters
·
Jun 19

Vaxcyte Shareholders Reelect Directors, Approve Governance Measures

TIPRANKS
·
Jun 17

Vaxcyte shareholders re-elect three Class III directors at annual meeting

Reuters
·
Jun 17

Vaxcyte’s New VAX-A1 Trial: Early Move Into Group A Strep Vaccines

TIPRANKS
·
Jun 17

Vaxcyte (PCVX) Valuation Check As VAX A1 Begins Phase 1 Group A Strep Trial

Simply Wall St.
·
Jun 08

Vaxcyte COO Jim Wassil disposes of common shares worth $111,467.81

Reuters
·
Jun 04

Analysts Offer Insights on Healthcare Companies: Repligen (RGEN), Vaxcyte (PCVX) and BeOne Medicines (ONC)

TIPRANKS
·
Jun 04

Vaxcyte (PCVX) Has a New Rating from Mizuho Securities

TIPRANKS
·
Jun 03

Vaxcyte doses first participant in VAX-A1 study

TIPRANKS
·
Jun 03

Vaxcyte publishes investor presentation highlighting broad-spectrum pneumococcal vaccine pipeline lead VAX-31

Reuters
·
Jun 03

Vaxcyte - Expects Topline Data From Vax-a1 Phase 1 Study in H2 2027

THOMSON REUTERS
·
Jun 03